Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dequidt Tanguy, Richier Quentin, Louapre Céline, Ader Florence, Merad Yanis, Lauwerier Nicolas, Jacomet Christine, Carles Michel, Biron Charlotte, Gendrin Vincent, Marlat Clément, Danion François, Lepage Tristan M, Sotto Albert, Bourdellon Loïc, Mania Alexandre, Martinot Martin, Falher Georges Le, Ferre Alexis, Pilmis Benoit, Gondran Guillaume, Simeone Pierre, Henry Matthieu, Kamel Toufik, Ray Simon, Ancellin Sophie, Mélé Nicolas, Camou Fabrice, Destremau Marjolaine, Sellenet Jeremy, Zucman Noémie, Le Maréchal Marion, Mellouki Khawla, Langlois Marie-Elodie, Luque Paz David, Mousset Maud, Leclerc Catherine, Sommet Agnès, Lacombe Karine, Martin-Blondel Guillaume
Аннотация
METHODS: This French national, retrospective cohort study was conducted between November 2020 and June 2023. Patients with MS or NMOSD, under anti-CD20 mAbs, with symptomatic COVID-19 and treated by CCP were screened. Protracted COVID-19 was defined by a duration of symptoms >21 days. The primary endpoint was the overall survival 30 days after CCP administration.
RESULTS: Ninety-two patients from 34 hospitals were included, 84 (91%) with MS and 8 (9%) with NMOSD. Overall, 30-day survival was 97% (IC95%: 91-99). SARS-CoV-2 viremia was positive in 47/75 (61%) patients before CCP versus 9/59 (15%) seven days post-CCP. In the 52 patients (57%) with protracted COVID-19, the duration of symptoms before CCP was 51 [28-69] days, including fever in 75% of cases, which disappeared in 100% of patients 7 days post-CCP.
CONCLUSIONS: CCP could be a therapeutic option in patients exposed to anti-CD20 mAbs for inflammatory demyelinating disease, particularly in those with protracted COVID-19.